The effects of sildenafil citrate on intrauterine growth restriction: a systematic review and meta-analysis
Rakhanova Y. Almawi W.Y. Aimagambetova G. Riethmacher D.
December 2023BioMed Central Ltd
BMC Pregnancy and Childbirth
2023#23Issue 1
Background: An increase in vascular resistance of uterine vessels is associated with intrauterine growth restriction (IUGR). Sildenafil citrate, a phosphodiesterase-5 inhibitor that stabilizes cyclic guanosine monophosphate (cGMP) and increases nitric oxide levels, improves placental perfusion by dilation of spiral arteries and is beneficial in managing IUGR. This study aims to determine the effectiveness of sildenafil citrate in improving perinatal outcomes in IUGR pregnancies. Methods: Meta-analysis was performed on data extracted from all studies specific to sildenafil citrate in IUGR management, searching relevant articles on PubMed, Medline, Google Scholar, Embase, and Cochrane databases. Publications identified by the manual search, based on references in reviews, were also included. Dichotomous results were presented as risk ratio (95% confidence interval), while continuous results were expressed as mean difference (MD); samples represented by the random effects model. Results: Nine trials were included where the sildenafil citrate effect was compared with a placebo or no intervention. A significant increase in birth weight [SMD (95% CI), 0.69 (0.31, 1.07)] was seen in IUGR pregnancies managed with sildenafil. However, gestational age (SMD (95% CI), 0.44 (-0.05, 0.94], fetal death rate [RR (95% CI), 0.56 (0.17, 1.79)] in IUGR pregnancies was not changed by sildenafil. Neonatal death [RR (95% CI), 0.93 (0.47, 1.86)] and neonatal intensive care unit (NICU) admissions [RR (95% CI), 0.76 (0.50, 1.17)] were not significantly different between sildenafil and control groups. Conclusion: Sildenafil citrate increases birth weight and prolonged pregnancies but did not affect stillbirth rate, neonatal death, and NICU admission. Trial registration: The study was registered in PROSPERO on September 18, 2021 (CRD42021271992).
IUGR , Low birthweight , Phosphodiesterase-5 inhibitor , Pregnancy outcomes , Sildenafil citrate
Text of the article Перейти на текст статьи
School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Faculté Des Sciences de Tunis, Université de Tunis - El Manar, Tunis, Tunisia
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Department of Surgery, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
School of Medicine
Faculté Des Sciences de Tunis
Department of Biomedical Sciences
Department of Surgery
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026